Skip to main content
SpringerLink
Log in

Therapeutic drug monitoring: Pharmacologic considerations for antiretroviral drugs

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Therapeutic drug monitoring (TDM) is the process by which a patient’s dosing regimen is guided by repeated measures of plasma drug concentrations. An enormous challenge with regard to TDM of antiretroviral drugs (ARV) is that the concentration goals can be moving targets. Well-designed prospective studies demonstrating that prospectively altering ARV doses based on TDM leads to virologic success and increased tolerability are needed. Nevertheless, there are specific clinical instances where this experimental intervention should be considered to potentially reduce toxicity and improve therapeutic outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Acosta EP, Gerber JG: Position Paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002, 18:825–834.

    Article  PubMed  CAS  Google Scholar 

  2. Aarnoutse RE, Schapiro JM, Boucher CAB, et al.: Therapeutic drug monitoring: An aid to optimizing response to antiretroviral drugs? Drugs 2003, 63:741–753.

    Article  PubMed  CAS  Google Scholar 

  3. Fraaij PLA, Rakhmanina N, Burger DM, de Groot R: Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004, 26:122–126.

    Article  PubMed  Google Scholar 

  4. Back D, Gatti G, Fletcher CV, et al.: Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002, 16(Suppl 1):5–37. Complete review of TDM literature and utility of TDM for antiretroviral drugs.

    Article  Google Scholar 

  5. Gerber JG, Acosta EP: The potential role of therapeutic drug monitoring in the treatment of HIV infection. Topics in HIV Medicine 2002, 10:27–32. Paper includes an assessment of antiretroviral drugs as candidates for TDM based on the Spector criteria.

    Google Scholar 

  6. Gerber JG, Acosta EP: Therapeutic drug monitoring in the treatment of HIV-Infection. J Clin Virol 2003, 27:117–128.

    Article  PubMed  CAS  Google Scholar 

  7. Spector R, Park GD, Johnson GF, Vesell ES: Therapeutic drug monitoring. Clin Pharmacol Ther 1988, 43:345–353.

    Article  PubMed  CAS  Google Scholar 

  8. Anderson PL, Fletcher CV: Clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr Infect Dis Rep 2001, 3:381–387.

    Article  PubMed  Google Scholar 

  9. Smith PF, DiCenzo R, Morse GD: Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001, 40:893–905.

    Article  PubMed  CAS  Google Scholar 

  10. Fletcher CV, Anderson PL, Kakuda TN, et al.: Concentrationcontrolled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002, 16:551–560. An intensive, proof-of-concept study of therapeutic drug monitoring in treatment-naïve patients. All drugs in the antiretroviral regimen were monitored in this study.

    Article  PubMed  Google Scholar 

  11. Lucas GM, Chaisson RD, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81–87.

    PubMed  CAS  Google Scholar 

  12. Dorrucci M, Pezzotti P, Grisorio B, et al.: Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and nonnucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001, 15:1733–1736.

    Article  PubMed  CAS  Google Scholar 

  13. Deeks SG, Heckt FM, Swanson M, et al.: HIV, RNA, and CD4 cell count response to protease inhibitor therapy in and urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:35–43.

    Article  Google Scholar 

  14. Marzolini C, Telenti A, Decosterd LA, et al.: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71–75. An example of concentration-effect relationships for efavirenz with efficacy and toxicity. These data led to a concentration range for the TDM of efavirenz.

    Article  PubMed  CAS  Google Scholar 

  15. Gatti G, Di Biagio A, Casazza R, et al.: The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999, 13:2083–2089.

    Article  PubMed  CAS  Google Scholar 

  16. Dieleman JP, Gyssens IC, van der Ende ME: Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473–478.

    Article  PubMed  CAS  Google Scholar 

  17. Acosta EP: Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr, 2002 29(Supp l):11–18.

    Google Scholar 

  18. Burger D, Hugen P, Reiss P, et al.: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003, 17:1157–1165. A reasonably large study showing the utility of TDM in naïve patients. The study also suggested that TDM could detect and allow correction of drug-food interactions for nelfinavir.

    Article  PubMed  CAS  Google Scholar 

  19. Clevenberg P, Garraffo R, Durant J, Dellamonica P: Pharm- Adapt: A randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12-week results. AIDS 2002, 16:2311–2315.

    Article  Google Scholar 

  20. Bossi P, Peytavin G, Ait-Mohand H, et al.: GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004, 5:352–359.

    Article  PubMed  CAS  Google Scholar 

  21. Hill AM, Stirnadel HA: Are clinical trials of TDM underpowered to detect effects on HIV RNA?: three-stage modeling analysis of sample sizes [abstract]. Proceedings from the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, April 2–4, 2001.

  22. Risebrough NA, Philips E: Potential cost-effectiveness of therapeutic drug monitoring (TDM) of protease inhibitors in the treatment of HIV [abstract]. Proceedings from the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, April 2–4, 2001.

  23. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21–30.

    PubMed  CAS  Google Scholar 

  24. Chesney MA, Ickovics JR, Chambers DB, et al.: Self-reported adherence to antiretroviral drug medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255–66.

    Article  PubMed  CAS  Google Scholar 

  25. Maggiolo F, Ravasio L, Ripamonti D, et al.: Similar adherence rates favor different virologic outcomes for patients treated with non-nucleoside analogues or protease inhibitors. CID 2005, 40:158–163. Large study which suggests that NNRTI-based regimens may be more forgiving than PI-based regimens.

    Article  CAS  Google Scholar 

  26. Fischl M, Castro J, MonroigR, et al.: Impact of directly observed therapy on long-term outcomes in HIV-clinical trials [abstract]. Proceedings from the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4–8, 2001.

  27. Thomas DL, Vlahov D, Solomon L, et al.: Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995, 74:212–220.

    Article  CAS  Google Scholar 

  28. Regazzi MB, Villani P, Zucchi P, et al.: Clinical pharmacokinetics of nelfinavir and its metabolite M8 in HIV/HCV co-infected patients with and without cirrhosis [abstract]. Proceedings from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, March 27–29, 2003.

  29. Da Silva B, King M, Cenohous P, Srun S: Lopinavir/ritonavir (LPV/r) safety, tolerability, and efficacy in HIV patients coinfected with hepatitis C and or hepatitis B: review of clinical trials [abstract]. Proceedings from the XV International AIDS Conference, Bangkok, Thailand. July 11–16, 2004.

  30. Chihrin S, Loutfy MR, Raboud J, et al.: Exposure to lopinavir/r is a risk factor for grade -3 to -4 elevation of alanine aminotransferase (ALT) in HIV and hepatitis B (HBV) and/or C (HCV) co-infected patients [abstract]. Proceedings from the XV International AIDS Conference, Bangkok, Thailand, July 12–16, 2004.

  31. Piscitelli SC, Burstein AH, Chaitt D, et al.: Indinavir concentrations and St. John’s Wort. Lancet 2000, 355:547–548.

    Article  PubMed  CAS  Google Scholar 

  32. Piscitelli SC, Burstein AH, Welden N, et al.: The effect of garlic supplements on the pharmacokinetics of saquinavir. CID 2002, 34:234–238.

    Article  Google Scholar 

  33. Bryson YJ, Stek A, Mirochnick M, et al.: PACTG 353: a phase I study of safety, pharmacokinetics, and antiviral activity of combination nelfinavir (NFV), ZDV, and 3TC in HIV-Infected pregnant women and their infants [abstract]. Proceeding from the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January 30–February 2, 2000.

  34. Acosta EP, Zorrilla C, Van Dyke R, et al.: Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001, 2:460–465.

    Article  PubMed  CAS  Google Scholar 

  35. Stek A, Mirochnick M, Capparelli E, et al.: Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. In: XV International AIDS Conference, Bangkok, Thailand. July 11–16, 2004 [abstract LbOrBO8].

  36. National Institutes of Health: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Accessible at http://www.aidsinfo.nih.gov. Accessed January 7, 2005.

  37. Kearns GL, Abdel-Rahman SM, Alander SW, et al.: Developmental pharmacology-drug disposition, action, and therapy in infants and children. NEJM 2003, 349:1157–1167.

    Article  PubMed  CAS  Google Scholar 

  38. van Rossum AMC, Fraaij PLA, de Groot R: Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet 2002, 2:93–102.

    Article  Google Scholar 

  39. Watson DC, Farley JJ: Efficacy of and adherence to highly active antiretroviral therapy in children infected with HIV type I. Pediatr Infect Dis J 1999, 18:682–689.

    Article  PubMed  CAS  Google Scholar 

  40. Holland DT, DiFrancesco R, Stone J, et al.: Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004, 48:824–831.

    Article  PubMed  CAS  Google Scholar 

  41. Droste JAH, Aarnoutse RE, Koopmans PP: Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. AIDS 2003, 32:287–291.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, University of Colorado Health Science Center, 4200 East 9th Ave, Box C237, 80262, Denver, CO, USA

    John G. Gerber MD

Authors
  1. Jennifer J. Kiser Pharm.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter L. Anderson Pharm. D
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John G. Gerber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiser, J.J., Anderson, P.L. & Gerber, J.G. Therapeutic drug monitoring: Pharmacologic considerations for antiretroviral drugs. Curr HIV/AIDS Rep 2, 61–67 (2005). https://doi.org/10.1007/s11904-005-0020-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-005-0020-8

Keywords

Search

Navigation